{"transactions":[{"id":1673990,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-22T16:18:16.000Z","date":"2024-01-19","kind":"sale","planned":false,"acquired":false,"shares":5000000,"price":3.95,"value":19750000.0,"ownership":{"direct":true},"balance_after":21687906,"source":{"system":"sec-edgar","filing":"0000950170-24-006070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000095017024006070/ownership.xml","form_type":"4"}},{"id":2310792,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-01T16:08:50.000Z","date":"2022-03-03","kind":"other","acquired":false,"shares":1158089,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the resignation of Dr. Tillman Gerngross from the Issuer's Board of directors, the Issuer repurchased 1,158,089 shares of restricted common stock from the Reporting Person for aggregate consideration of $2,316.18."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the resignation of Dr. Tillman Gerngross from the Issuer's Board of directors, the Issuer repurchased 1,158,089 shares of restricted common stock from the Reporting Person for aggregate consideration of $2,316.18."}],"balance_after":26687906,"source":{"system":"sec-edgar","filing":"0000899243-22-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000089924322013098/doc4.xml","form_type":"4"}},{"id":2605033,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-08-12T21:22:40.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":128064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":640320},"source":{"system":"sec-edgar","filing":"0001209191-21-051295","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000120919121051295/doc4.xml","form_type":"4"}},{"id":2605032,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-12T21:22:40.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":44076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":220380},"source":{"system":"sec-edgar","filing":"0001209191-21-051295","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000120919121051295/doc4.xml","form_type":"4"}},{"id":2605031,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-08-12T21:22:40.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000000},"source":{"system":"sec-edgar","filing":"0001209191-21-051295","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000120919121051295/doc4.xml","form_type":"4"}},{"id":2605030,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":95005,"kind":"organization","name":"Adimab, LLC","position":1,"cik":"0001545672","reported_name":"Adimab, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-12T21:22:40.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":25860700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date."}],"balance_after":27845995,"source":{"system":"sec-edgar","filing":"0001209191-21-051295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1545672/000120919121051295/doc4.xml","form_type":"4"}}]}